Generic drugmaker to pay $3m antitrust fine
New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
US Senate Committee votes in Stephen Hahn as FDA Commissioner
The US Senate Committee on Health, Education, Labor and Pensions has approved President Donald Trump’s nomination for Stephen Hahn to serve as the new commissioner of the Food and Drug Administration.
Astellas doubles down on gene therapy with $3bn Audentes deal
Astellas is set to buy US-based Audentes Therapeutics for approximately $3 billion, as the Japanese pharmaceutical company looks to boost its gene therapy expertise.
Barnes & Thornburg adds 17, creates three new offices
Barnes & Thornburg has recruited a new life sciences patent group from the IP boutique Brinks, Gilson & Lione.
US considers shortening marketing exclusivity to push forward USMCA
The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.
Genus sues Mallinckrodt over secret cocaine hydrochloride studies
Genus Lifesciences is suing pharmaceutical company Mallinckrodt for misusing trade secrets related to a cocaine hydrochloride formulation.
Munich court rules for Bio-Rad in 10x Genomics dispute
California-based Bio-Rad Laboratories has obtained an injunction from a German court in its long-running dispute with US biotechnology company 10x Genomics.
China lowers price of 70 drugs by expanding national insurance catalogue
China has added 70 medicines to its national medical insurance catalogue, which will reduce the cost of the drugs by more than 60% on average, the National Healthcare Security Administration has said.
Asahi Kasei in $1.3bn Veloxis acquisition
Japanese pharmaceutical conglomerate Asahi Kasei has announced it will acquire Danish company Veloxis Pharmaceuticals for $1.3 billion.
Amgen settles with Coherus over arthritis treatment
Amgen and Coherus Biosciences have settled a patent infringement dispute, after Coherus claimed that Amgen was infringing three of its patents.
